PMID- 15073926
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20040712
LR  - 20040409
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 8
IP  - 3
DP  - 1999 May
TI  - An application of meta-analysis techniques in the evaluation of adverse 
      experiences with antihypertensive agents.
PG  - 169-77
AB  - PURPOSE: To investigate the profiles of adverse events (AEs) in randomized 
      controlled trials of antihypertensive agents therapy with the technique of 
      meta-analysis. METHODS: A total of 620 articles were selected from MEDLINE, 
      EMBASE, JAPIC-DOC, JMEDICINE and manual searching. Two independent reviewers 
      examined the 620 selected articles according to the following criteria: (1) the 
      methods of randomization, (2) making for allocating treatments, (3) therapeutic 
      class of drugs, (4) sample sizes, (5) duration of the treatment, (6) primary 
      endpoint, (7) reporting method for all adverse events, (8) method of monitoring 
      AEs, and (9) incidence rates of all reported AEs. To combine the risk difference 
      and risk ratios of incidence between CCBs and beta blockers or diuretics, the 
      method of DerSimonian and Laird based on random effect model was applied. 
      RESULTS: A total of 3073 patients were included in this meta-analysis of serious 
      adverse events (SAEs). There was no significant difference in the total incidence 
      of SAEs between CCBs and diuretics or between CCBs and beta blockers. We found 
      that patients treated with CCBS had 0.14% fewer SAEs compared with the patients 
      treated with diuretics. Contrarily, the patients treated with CCBs had 0.29% more 
      SAEs compared with the patients treated with beta blockers. There was a 
      significant difference between the patients treated with CCBs and those treated 
      with diuretics in the symptoms with headache and oedema. With respect to the 
      comparison between CCBs and beta blockers, flushing occurred 8.75% more 
      frequently in the CCBs group than in the beta blockers group. CONCLUSION: A 
      meta-analysis can be applied to safety analyses of data obtained in clinical 
      trials if all of the RCT articles used include a complete description of adverse 
      experiences.
CI  - Copyright 1999 John Wiley & Sons, Ltd.
FAU - Sakai, H
AU  - Sakai H
AD  - Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, 
      7-3-1, Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan.
FAU - Hayashi, K
AU  - Hayashi K
FAU - Origasa, H
AU  - Origasa H
FAU - Kusunoki, T
AU  - Kusunoki T
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
CIN - Pharmacoepidemiol Drug Saf. 1999 May;8(3):167-8. PMID: 15073925
EDAT- 2004/04/10 05:00
MHDA- 2004/04/10 05:01
CRDT- 2004/04/10 05:00
PHST- 2004/04/10 05:00 [pubmed]
PHST- 2004/04/10 05:01 [medline]
PHST- 2004/04/10 05:00 [entrez]
AID - 10.1002/(SICI)1099-1557(199905/06)8:3<169::AID-PDS416>3.0.CO;2-F [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 1999 May;8(3):169-77. doi: 
      10.1002/(SICI)1099-1557(199905/06)8:3<169::AID-PDS416>3.0.CO;2-F.